Park City, UT

3 days / 6 sessions
Current Issues in Spine

February 2-4, 2017


December 18, 2018 OrthoSpineNews

18 December 2018

Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces that it has agreed to acquire Ceterix® Orthopaedics, Inc, the developer of the NovoStitch® Pro Meniscal Repair System.

This unique device addresses complex meniscal tear patterns not adequately served by other repair systems. It is highly complementary to Smith & Nephew’s leading FAST-FIX 360 Meniscal Repair System, which addresses vertical tears, the most commonly repairable meniscal injury today.

Currently more than 1.2 million1 meniscal tears are treated surgically in the US each year. In only 15-20%1 of the cases is the meniscus repaired, rather than removed.  With products like NovoStitch Pro and FAST-FIX 360 we see the opportunity to double this proportion in the medium term.

Smith & Nephew will pay an initial cash consideration of $50 million and up to a further $55 million over the next five years, contingent on financial performance.

“NovoStitch Pro is an outstanding technology that addresses an unmet clinical need,” said Brad Cannon, President Sports Medicine and ENT, Smith & Nephew. “We are excited by the opportunities to take this new option to our customers. No other company is better positioned to support changing clinical practice as the standard for meniscal treatment pivots from resection to repair.”

The NovoStitch Pro allows surgeons to repair arthroscopically a broader range of meniscal tear types, including horizontal, radial, complex, bucket handle and root tears, as well as vertical tears.

“The new NovoStitch Pro Meniscal Repair System is one of the most innovative technologies developed for arthroscopic knee repair,” said Dr. Peter Kurzweil, president of Memorial Orthopaedic Surgical Group in Long Beach, California. “NovoStitch offers the potential to repair tear types that were previously considered difficult or impossible to sew, with good control and access for the surgeon.”

The NovoStitch Pro will be sold through Smith & Nephew’s extensive sports medicine sales force as well as Ceterix’s existing dedicated sales force. NovoStitch Pro has 510(k) clearance for sale in the US.

“We are proud of the impact our technology has made in developing the meniscal repair market and are excited by the opportunity to reach many more customers and their patients as an integrated part of Smith & Nephew’s extensive Sports Medicine portfolio,” said John McCutcheon, Chief Executive Officer of Ceterix.

The transaction is expected to close in early 2019, subject to the satisfaction of customary conditions. The acquisition will be financed from existing cash and debt facilities.

Andrew Swift
+44 (0) 20 7960 2285
Smith & Nephew

Charles Reynolds
+44 (0) 1923 477314
Smith & Nephew

Ben Atwell/ Andrew Ward
+44 (0) 20 3727 1000
FTI Strategic Consulting

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to supporting healthcare professionals in their daily efforts to improve the lives of their patients. With leadership positions in Orthopaedic ReconstructionAdvanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE 100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.comfollow @SmithNephewplc on Twitter or visit SmithNephewplc on


1. 2018 SmartTRAK US Meniscal Repair Fixation market report

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations. 

 Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office.


December 13, 2018 OrthoSpineNews

Dublin, Dec. 13, 2018 (GLOBE NEWSWIRE) — The “Sports Medicine Devices Market to 2025 – Global Analysis and Forecasts By Product, Application, and Geography” report has been added to’s offering.

The global sports medicine devices market is expected to reach US$ 10,662.5 Mn in 2025 from US$ 5,822.6 Mn in 2017. The market is estimated to grow with a CAGR of 7.9% from 2018-2025.

The growth of the sports medicine devices market is primarily attributed to increasing incidence of sports injuries. Moreover, the presence of large number of sports medicine associations is expected to fuel the market growth. The introduction of advanced technology in the sports medicine market is expected to offer significant growth opportunity in the sports medicine devices market during the forecast period.

The innovations of the new technologies are expected to introduce new therapies and procedures that will help to reduce time and costs and provide optimized and personalized results to continue to shape the medical device industry. Also the intelligent orthopedics in combination with traditional techniques and high-end technology will enable to change the future of industry.

The associations for the sports medicine are increasing across the countries in the world. The associations are involved in spreading the awareness about the sport medicine which is helping sports players and athletes to recover from their injuries. Some of the global groups and associations for the sports medicine are International Council of Sports Science and Physical Education (ICSSPE), International Federation of Sports Medicine (FIMS) and World Federation of Athletic Training & Therapy (WFATT).

Global sports medicine devices market, based on product was segmented as, body reconstruction and repair, body support and accessories. In 2017, body reconstruction and repair segment held the largest share by the market, by product. This is mainly attributed to the benefits offered such as, reduction in pain and improved functioning. In addition, it also amplify the body’s natural healing abilities and enhances the growth of new cartilage, ligaments and tendons.

Global sports medicine devices market, based on application was segmented knee, shoulder, ankle/foot, elbow & wrist, and others. In 2017, knee segment held the largest share of market, by application. In addition, the segment is anticipated to witness a significant growth among other applications, during the forecast period.

Some of the major primary and secondary sources for sports medicine devices included in the report are World Health Organization (WHO), Organisation for Economic Co-operation (OECD), National Research Foundation (NRF), International Diabetes Federation (IDF), Canadian Institutes of Health Research (CIHR) and others.

Key Topics Covered:

1. Introduction 
1.1 Scope Of The Study
1.2 Research Report Guidance

2. Global Sports Medicine Devices Market – Key Takeaways 

3. Global Sports Medicine Devices- Market Landscape 
3.1 Overview
3.2 Market Segmentation
3.3 Pest Analysis

4. Global Sports Medicine Devices Market – Key Market Dynamics 
4.1 Key Market Drivers
4.1.1 Increase In The Number Of Sports Medicine Associations
4.1.2 Increasing Incidences Of Sports Injuries
4.1.3 Rising Demand For Minimally Invasive Methods
4.2 Key Market Opportunities
4.2.1 Penetration Into Emerging Economies
4.2.2 Introduction Of Advanced Technologies
4.3 Future Trends
4.3.1 Prevention Through Genomics
4.4 Impact Analysis

5. Sports Medicine Devices Market – Global Analysis 
5.1 Global Sports Medicine Devices Market Revenue Forecasts And Analysis
5.2 Global Sports Medicine Devices Market, By Geography – Forecasts And Analysis
5.3 Performance Of Key Players
5.3.1 Arthrex Inc.
5.3.2 Smith And Nephew
5.4 Expert Opinions

6. Global Sports Medicine Devices Market Analysis – By Product 
6.1 Overview
6.2 Global Sports Medicine Devices Market, By Product, 2017 & 2025 (%)
6.3 Body Reconstruction And Repair Market
6.3.1 Overview
6.3.2 Global Body Reconstruction And Repair Market Revenue And Forecasts To 2025 (US$ Mn)
6.3.3 Fracture And Ligament Repair Devices Market
6.3.4 Orthobiologics Market
6.3.5 Arthroscopy Devices Market
6.3.6 Prosthetic Market
6.4 Body Support Market
6.4.1 Overview
6.4.2 Global Body Support Market Revenue And Forecasts To 2025 (US$ Mn)
6.4.3 Braces Market
6.4.4 Topical Pain Relief Market
6.4.5 Compression Clothing Market
6.4.6 Thermal Therapy Devices Market
6.4.7 Others Market
6.5 Accessories Market

7. Global Sports Medicine Devices Market Analysis – By Application 
7.1 Overview
7.2 Global Sports Medicine Devices Market, By Application, 2017 & 2025 (%)
7.3 Elbow & Wrist Market
7.4 Shoulder Market
7.5 Knee Market
7.6 Ankle/Foot Market
7.7 Others Market

8. North America Sports Medicine Devices Market Revenue And Forecasts To 2025 

9. Europe Sports Medicine Devices Market Revenue And Forecasts To 2025 

10. Asia-Pacific Sports Medicine Devices Market Revenue And Forecasts To 2025 

11. Middle East & Africa Sports Medicine Devices Market Revenue And Forecasts To 2025

12. South And Central America Sports Medicine Devices Market Revenue And Forecasts To 2025 

13. Sports Medicine Devices Market – Industry Landscape 
13.1 Overview
13.2 Growth Strategies In The Sports Medicine Devices Market, 2015-2018
13.3 Organic Growth Strategies
13.3.1 Overview
13.3.2 Product Launches
13.3.3 Expansion
13.4 Inorganic Growth Strategies
13.4.1 Overview
13.4.2 Partnership
13.4.3 Acquisitions

14. Sports Medicine Devices Market, Key Company Profiles 

  • DJO Global
  • Zimmer Biomet
  • Smith & Nephew
  • DePuy Synthes
  • Wright Medical Group N.V.
  • Arthrex, Inc.
  • CONMED Corporation
  • Mueller Sports Medicine, Inc.
  • RTI Surgical, Inc.

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Sports Medicine and Physiotherapy


December 7, 2018 OrthoSpineNews

Magal, Israel, December 7, 2018 – MinInvasive Ltd., developer of the OmniCuff™ device for treatment of rotator cuff repair, reported positive progress following its initial two months of limited market release activity in the US with 26 OmniCuff™ System cases successfully concluded to date.

Shoulder rotator cuff repair is a fast-growing market segment within the sports medicine market, with over one million procedures performed annually worldwide. The OmniCuff™ System is an arthroscopic transosseous rotator cuff repair device that eliminates the need for suture anchors. The device provides the advantages of minimally invasive transosseous repair in a disposable device. MinInvasive CEO Ronen Raz stated, “We are very pleased that within the first 8 weeks of limited US market release, the OmniCuff™ System has been successfully used by several very reputable sports medicine surgeons in 26 rotator cuff repair procedures”.

Joseph Abboud, MD, Professor of Orthopedic Surgery at the Rothman Institute at Thomas Jefferson University in Philadelphia, recently performed several OmniCuff cases and confirmed that he is “extremely pleased with the technical ease and reproducibility of the device, as well as the tremendous potential for direct cost savings.”

Walter Stanwood, an Orthopedic surgeon at Beth Israel Deaconess Hospital in Plymouth, Massachusetts has completed over a dozen surgeries with the Omnicuff, and commented that the System offers “a very straightforward technique that minimizes steps, with an elegant device to consistently create transosseous fixation in a rotator cuff repair model. OmniCuff has enormous potential in any location that a tendon-bone repair is performed.”

Nikhil Verma, MD Professor and Director of the Division of Sports Medicine and Shoulder Surgery at Rush University Medical Center in Chicago, remarked that the device “allows for a seamless transition between traditional anchor-based repair, and an anchorless solution. In addition, the availability of a technologically advanced and easy to use anchorless device has the potential to disrupt the market with a lower cost solution which is of paramount importance given recent movement of these types of cases to outpatient facilities and the emphasis on value-based care.”

Frank Cordasco, MD, MS, Professor of Orthopaedic Surgery at the Hospital for Special Surgery and the 35th President of the American Shoulder and Elbow Surgeons has observed “remarkably diminished pain in the post-operative period in patients treated with the OmniCuff System compared to those treated with the transosseous equivalent rotator cuff repair technique during the first 3 weeks following surgery. This has resulted in a decreased need for Opioid medications in the patients treated with the OmniCuff System”.

MinInvasive plans to gradually expand the availability of the device in the US and is currently in the process of securing CFDA approval for OmniCuff™ in China, another huge potential market for innovative medical technologies.

MinInvasive Ltd.

MinInvasive has developed the OmniCuff™ System – an innovative device enabling arthroscopic, transosseous rotator cuff repair. In 2016, MinInvasive entered into a strategic partnership with MicroPort Scientific Corporation to obtain CFDA approval for the OmniCuff™ system. MinInvasive has validated manufacturing of its new OmniCuff™ disposable version and initiated a limited market release in early October in the US.


Ronen Raz, CEO, MinInvasive Ltd. 137 Hashachaf, Magal, Israel



November 12, 2018 OrthoSpineNews

NEW YORK and KFAR SABA, IsraelNov. 12, 2018 /PRNewswire/ — CartiHeal, developer of Agili-C, a proprietary implant for the treatment of joint surface lesions, announced today the successful enrollment of the first patient in the Agili-C Investigational Device Exemption (IDE) pivotal study on the East Coast.

The surgery was performed by site Principal Investigator Eric J. Strauss, MD, an orthopedic surgeon at NYU Langone Health’s Sports Medicine Center in New York City. NYU Langoprnewne is one of 15 U.S. sites in the new Food and Drug Administration (FDA) IDE trial and will enroll 20 patients with major knee cartilage injuries.

The first patient enrolled at NYU Langone was a 53 year-old female with a history of two failed surgeries on her left knee, who had a very symptomatic cartilage lesion, with significant bone marrow edema affecting her lateral femoral condyle. “The patient was randomized to the Agili-C arm and treated with a single implant in a procedure that went smoothly and led to an immediate increase in blood flow to the affected region,” according to Dr. Strauss.

“My colleagues and I are looking forward to building upon this first successful case and contributing to the study on treating these difficult-to-manage injuries. This investigational implant has great potential to provide an off-the shelf solution for a large spectrum of cartilage lesions.”

Nir Altschuler, CartiHeal’s founder & CEO said: “Enrolling the first US East Coast patient is an important milestone for our study. We are honored that this important case was performed in the good hands of Dr. Eric Strauss, and look forward to his research team continuing to enroll patients.”  Altschuler also added that the IDE study, with over 100 enrolled patients, is currently ongoing in the US, EU and Israel, and aiming for an FDA premarket approval application.

CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.

About CartiHeal 
CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.

In the United States, the Agili-C implant is not available for sale – it is an investigational device limited for use in the IDE study.

SOURCE CartiHeal

Related Links


November 7, 2018 OrthoSpineNews

November 07, 2018

VISTA, Calif.–(BUSINESS WIRE)–DJO®, a leading provider of medical technologies designed to get and keep people moving, announced the partnership with SirenMD, becoming the exclusive sales representative for SirenMD’s sports team market. SirenMD is a workplace collaboration platform designed to increase the quality, efficiency, and timeliness of medical decisions by facilitating coordinated communication between caregivers and patient advocates.

With this new partnership, DJO can now offer existing customers and sales channels a new and innovative coordinated care platform. SirenMD’s software provides more compliant, collaborative and efficient sharing and transfer of patient information. “We are excited to partner with SirenMD so we can provide even greater care to athletes and sports teams,” notes Michael McBrayer, SVP at DJO. “This platform enables care providers to quickly communicate with other healthcare providers on specific cases or patients, and still be HIPAA compliant.”

SirenMD aggregates injury data and provides redacted and confidential injury reports to the conference and member institutions. The platform will use its internal case data for specific injuries for a given set of teams. Injury patterns and frequency can be identified for all body parts, including: shoulder dislocations, knee ligament tears, and ankle sprains.

SirenMD is an app-based enabled platform featuring:

  • Case-based workflow in real-time to minimize costly workplace disruption
  • HIPAA secure infrastructure protects private, patient data
  • Centralized platform enables documentation of communications
  • Intuitive design allows for quick and easy prioritization
  • Timely coordination leads to faster and better care for patients

Of the partnership, Lee Kaplan, MD, CEO of SirenMD, said, “There is a very synergistic opportunity for both SirenMD and DJO. Through this partnership, we can now address some of the medical inefficiencies with a holistic communications platform and improve overall patient care.”

The new partnership begins immediately. Please contact Brian Moore (DJO) or Andrew Willert (SirenMD) for more information.

About DJO

DJO is a leading global developer, manufacturer and distributor of high-quality medical devices that provide solutions for musculoskeletal health, vascular health and pain management. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals.

In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga®, CMF™, Compex®, DonJoy®, ProCare®, DJO Surgical®, Dr. Comfort® and Exos®. Visit

About SirenMD

SirenMD is a workplace collaboration platform designed to increase the quality, efficiency, and documentation of medical decisions. The platform allows medical professionals (such as physicians, athletic trainers, and physical therapists) in a variety of specialties to better coordinate and document critical interactions related to patient health. SirenMD envisions a world where caregivers at all levels are able to connect and collaborate quickly and securely. Such coordination allows for faster decision-making, fewer headaches, and, ultimately, better care. Founded by physicians, and led by healthcare and technology experts, SirenMD’s team is focused on delivering valuable clinical workflow tools to all healthcare teams. Visit

Individual results may vary. Neither DJO Global, Inc. nor any of its subsidiaries dispense medical advice. The contents of this document do not constitute medical, legal, or any other type of professional advice. Rather, please consult your healthcare professional for information on the courses of treatment, if any, which may be appropriate for you. The opinions and experiences presented here are for informational purposes only.


Media Contact:
Leda Buster, Marketing Communications Manager
(760) 597-3904
Press Contacts:
Brian Moore
Dwayne Treolo
Michael McBrayer
Andrew Willert
(305) 328-0009


October 16, 2018 OrthoSpineNews


According to the latest study published by AnalystView Market Insights, by the end of 2025, global sports medicine market is expected to reach USD 11.98 billion with the CAGR of 7.5%.

Sports medicine includes the medicines that can be used for treatment and prevention of injuries related to the exercise and sports. Sports medicine is a broad team that involves kinesiologists, physiologists, athlete trainers, physical therapists, physical educators, and many others. The market for sports medicine is primarily driven by the rise in a number of sports injuries across the globe. According to the National Ski Areas Association (NSAA), around 56,714 people were injured while participating in the winter sports that required immediate attention. Winter sports included sports like snowboarding, snowmobiling, and ice skating.

The main objective of introducing sports medicine is to prevent and treat injuries caused to the participants while performing the sports activities. Thereby, a steady introduction of new treatment modalities and products is expected to surge in demand for sports medicine. This, in turn, is expected to drive the market growth. In addition to this, constant developments in regenerative medicine field are expected. This will establish a healthy platform for market growth during the forecast period in this sector. It is also noticed that many multinational companies are planning to increase their investment in the development of 3D printed orthopedic implants which support the market growth to great extent. For instance, in January 2017, Sweden based OssDsign AB received US FDA approval of 3D Printed Cranial Implant Technology to commercialize the product in the U.S. market.

Get access to exclusive PDF brochure of this study @

This introduction is a definite approval as regards the products in this market arena. For instance, a product for cranial bone reconstruction will provide a healthy platform for future market growth. This product segment is divided into Body Monitoring, Body Reconstruction, Body Support, as well as the Sports Accessories. Body reconstruction and support devices collectively captured more than 50% share of the global market. High usage coupled with technological advancement has supported the market growth of these segments. Body monitoring segment is categorized as Cardiac, Hemodynamic, Musculoskeletal, and others. Body Reconstruction is further divided into Surgical equipment, Soft tissue repair, and Bone reconstruction devices. Body support device category is classified into various products like Braces devices, Compression clothing, and Hot & cold therapy. Hot and cold therapy is mainly used to control swelling. It also helps in dilating the blood vessels which supply ample blood to the site providing a stimulus to the process of healing the damaged tissue.

Accessories in this category include bandages, tapes, disinfectants, wraps, along with other instruments such as scissors, cutters, blister packs, etc. Bandages have dominated accessories segment in the year 2016. A sharp increase in incidents of injuries is observed. Thus, infection preventing product range is anticipated to contribute to the growth of this segment. Sports medicine market involving the application segment is categorized as Knees, Shoulders, Back & Spine, Hips, and Others. Knee devices accounted for the largest share of the global market in the year 2016. This segment is anticipated to maintain its leading position with a rising volume of knee surgeries.

Regionally, the market is categorized as North America, Europe, Asia Pacific, and Rest of the World. Around 49.36% share of the global market revenue is captured by North American countries, dominated by the U.S. market. Increase in a number of orthopedic procedures is anticipated owing to the high prevalence of accidents caused during a physical activity. This has supported the sports medicine market growth in this region. For instance, according to the CDC, around 51.4 million orthopedic procedures were performed in the U.S. in the year 2015. The highest prevalence of orthopedic conditions coupled with the high adoption of advanced treatment procedures is fuelling the growth of the market in the U.S.

Asia Pacific region is seen as a promising market growing at 9.1% growth rate over the forecast period. Countries such as India, Japan, and China exhibit their great potential to capture significant revenue share of the total Asia Pacific market. For example, Japan has the presence of a large number of implant manufacturers in this segment. The country has higher healthcare expenditure as compared to the other countries in the region. Moreover, the high adoption rate of the new technology and presence of various accident-prone individual sports in the region are expected to fuel the growth of the sports medicine market.

Companies such as Medtronic, Smith & Nephew, Stryker, Conmed, Wright Medical Technology, and others are present in this market. Company merger & acquisition strategies are being utilized for expanding their geographic presence. It is important to note that Mergers and acquisitions also enable widening of product portfolio as well as the customer base of the companies.

Click here to obtain more highlight on “Sports Medicine Market, By Products, By Application and Geography – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025” study @…

Global Sports Medicine Market: Snapshot

Market, By Products
Body Monitoring (Cardiac, Hemodynamic, Musculoskeletal and Others), Body Reconstruction (Surgical equipment, Soft tissue repair and Bone reconstruction devices), Body Support (Braces devices, Compression clothing and Hot & cold therapy), and Sports Accessories (Bandages, Tapes, Disinfectants, Wraps and others)

Market, By Application
Knees, Shoulders, Back & Spine, Hips and others
Market, by Region
North America (U.S. and Canada), Europe (France and Germany), Asia Pacific (India and China), Middle East and Africa, Latin America and Rest of the World

Key players profiled in this report with special attention on competitive landscape includes, (can be further customized to include additional 10 profiles of companies):
– Medtronic
– Smith & Nephew
– Stryker Corporation
– Conmed
– Wright Medical Technology

USP of our key vendor analysis:
– Well-designed strategic framework design for these key players will help to understand the market movement including regional expansion, mergers & acquisitions, and new product developments
– Thorough SWOT i.e. Strength, Weakness, Opportunities and Threat for individual company profiling is analyzed in order to present a detailed market opportunity assessment.

Key benefits of the report:
• The report presents a macro and micro-level outlook regarding the industry. Thus, it becomes easy for our clients to perceive the business landscape and take a glimpse of their own standing in it.
• A thorough analysis of relevant statistical data to estimate the market paradigms
• Exceptional understanding of region and country-specific markets. The report will answer some of the toughest questions regarding the market shares, sizes, forecasts segmentations, and growth specific to the countries.
• Well-designed strategic framework analyzes the market movements including regional expansion, mergers & acquisitions, and new product developments

Research Methodology:
– Preliminary Data Mining: Secondary Research, Paid Databases, Primary Research
– Data Synthesis & Analysis: Top-Down Approach, Bottom-Up Approach, Supply Side and Demand Side
– Market Formulation: Market Dynamics, Total Addressable Market and Machine Learning Technique
– Data Verification: Quality Assurance and Reach a Conclusion

To inquire more about our research process and report store, please connect @

About Us
AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends for various industries such as Healthcare, Bulk Chemicals, Semiconductors, Electronics, and Foods and Beverages.

Contact Us
Mr. Jose (Press & Marketing Manager)
Corporate Sales, USA
AnalystView Market Insights
Tel: +91-757-498-5725 (Asia-Pacific Business Centre)

This release was published on openPR.


September 5, 2018 OrthoSpineNews

KIRKLAND, Quebec, Aug. 31, 2018 (GLOBE NEWSWIRE) — Ortho Regenerative Technologies Inc. (CSE: ORTH) (“Ortho RTi” or the “Corporation”) announces that Benedek (Ben) Simo has been appointed Interim Chief Financial Officer, effective immediately. Mr. Simo succeeds Jo-Anne Piché who is leaving the Corporation to pursue other professional projects.

“Jo-Anne has made many contributions to the Corporation and we wish her all the best in her future endeavors,” said Ortho RTi’s Executive Chairman and CEO, Dr. Brent Norton.  “At the same time, we are excited to have attracted an executive of Ben’s caliber to this position. With his depth of financial experience and proven track record of driving value in financial management, we believe that Ben is ideally suited to serve in this role.”

Mr. Simo has over 15 years of experience in financial management with both private and public companies across a variety of sectors.  Most recently, he was Manager, Financial Reporting at Resolute Forest Products, a NYSE- and TSX-listed global leader in the forest products industry with approximately US$3.5 billion in annual revenues.  Prior to that, he served as Financial Controller at Synchronica Inc, an AIM- and TSX-Venture Exchange-listed developer of next-generation mobile messaging solutions that was acquired by Myriad Group AG in 2012.  Previously, Mr. Simo held financial management positions at TouchTunes Interactive Networks, McCain Foods Limited and Ipex Group.  Mr. Simo earned a bachelor’s degree in economics from McGill University, his MBA from Saint Mary’s University, and has obtained a CPA auditor, CA designation.  

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at

Caution regarding forward-looking statements

This news release may contain certain forward-looking statements regarding the Corporation’s expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

For further Information, please contact:

Stephen Kilmer
Investor & Media Relations


August 29, 2018 OrthoSpineNews

Pune, India, Aug. 29, 2018 (GLOBE NEWSWIRE) — Market Research Future® has recently published its Premium Report on Global Sports Medicine Market which reveals that the sports medicine market is projected to grow at a promising CAGR of 8.9% during the forecast period of 2017 to 2023. Sports medicine is a necessary part of the sports and athletics sector due to its use in ensuring sportspeople and athletes are in the right physical condition to perform. The global sports medicine market is expected to reach an estimated USD 9,655.6 Mn by the end of 2023.

Global and regional sporting & athletic events have become highly commonplace with thousands of individuals participating in some capacity or the other. Recreational sports are often part of most curriculums in schools where participation is highly encouraged. Injuries in the line of extensive physical activities are inevitable. The global population is at an all-time high, and as such, growing incidences of sports injuries have been recorded which has increased the demand for sports medicine. Moreover, in response to rising sports-related injuries, there has been a noticeable increase in the number of sports medicine associations, thus driving market growth. Increasing awareness with regards to sports medicine as a niche part of the healthcare sector and rapid technological advancements in the healthcare sector is expected to be some other important drivers of the market.

High costs associated with sports medicine and unfavorable reimbursement policies are expected to hinder market growth. Lack of skilled professionals in sports medicine for the treatment of pediatric sports injuries is expected to pose a challenge to market growth. However, with growing awareness, the market represents untapped opportunities which are likely to expand the market, particularly in pediatric sports medicine in the coming years.

Get Exclusive Sample Report of Sports Medicine Market Report Enabled with Top 10 Players Geographical Overview and Respective Tables and Figures at

Key Players Overview Mentioned

MRFR has analyzed the competitive landscape of the global sports medicine market to reveal the various strategies employed by leading market players. Spreading awareness, the establishment of new sports medicine centers, and investments in research & development are some of the market strategies prominent players employ. Market players of note that have been included in the report are Smith & Nephew, Stryker, Medtronic, Zimmer Biomet, CONMED Corporation, Arthrex Inc., GE Healthcare, DePuy Synthes, and others.

Latest Industry News

  • The U.S based BWHealth, a sports injury prevention and treatment organization has received investments of USD 600,000 toward the scaling of its newest line of injury prevention products.
  • Stryker has acquired MITA LLC, a startup set up with the intention to offer a post free hip distraction system. The novel system carries great potential in sports medicine market.

Market Segmentation

MRFR’s segmental analysis has been performed on the basis of product, application, procedure, end-user, and region. By product, the Sports Medicine Market is segmented to include joint reconstructive & repair products, accessories & consumables, support & recovery products and others. The joint reconstructive & repair products segment has been sub-segmented into ligament repair devices, implants, fracture, prosthetic devices, arthroscopy devices, and others. The support and recovery products segment has been further divided to include topical pain relief products, monitoring devices, thermal therapy devices, braces & support, monitoring devices, and others.

By application, the market is divided into spine treatment, hip treatment, knee treatment, shoulder treatment, and others.

By procedure, the market is categorized into tendon to bone, cartilage repair, and tendinosis. The tendinosis segment accounts for over half of the total market share. Tendinosis is chronic in nature and afflicts tendons which experience continuous stress over time which is highly common is sportspeople and athletes who carry the same sporting activities for years on end.

By end user, the market is segmented into ambulatory care, trauma centers, hospitals & emergency care and others.

Globally, the market has been segmented region-wise into North America, Europe, Asia Pacific and the Middle East & Africa.

High Number of Sports Medicine Centers Boost North America to Leading Position

North America, with its inclusion of the U.S, accounts for a market share of 39%, thus making it the most significant region in the global sports medicine market. Sports and athletics possess high importance in this region with sports like football and baseball being highly popular. Physical education and athletics are encouraged from a young age and children often participate in various sporting activities. As a result, there is an increasing number of sports medical centers being established in the region to treat the rising occurrences of sports injuries thus augmenting market growth.

Meanwhile, the Asia Pacific is growing at the highest CAGR of 9.2% during the assessment period. The regions healthcare sector is witnessing swift growth, and awareness regarding sports injury and the growing importance of physical education has provided the sports medicine market with opportunities for growth.

Get Discount on Sports Medicine Market Report at

Related Reports

North America Sports Medicine & Therapies Market-Forecast to 2023

North America Sports Medicine & Therapies Market Research Report, By Product (Helping Fractures Heal, Surgical Devices, Arthroscopy Devices, Orthopaedic Braces), By Area Of Application (Spine, Foot And Knee, Hip, Shoulder And Elbow, Other), By Procedure (Tendinosis, Tendon To Bone, Cartilage Repair), By End User (Hospitals & Emergency Care, Trauma Centres, Ambulatory Care)- Forecast To 2023

Global Precision Medicine Market Research Report – Forecast to 2022

Global Precision Medicine Market Information, By Ecosystem (pharma & biotech companies, diagnostic tool companies, healthcare IT/ big data companies, clinical laboratories), By Sub-markets (companion diagnostics, biomarker-based test, targeted therapeutics, pharmacogenomics, molecular diagnostics, others), By Therapeutics (cancer/oncology, cardiovascular disease, central nervous system, infectious diseases, others) – Forecast to 2022

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312



July 12, 2018 OrthoSpineNews

WARSAW, Ind., July 12, 2018 (GLOBE NEWSWIRE) — WishBone Medical, Inc. is pleased to announce that Sanford Kunkel, M.D. joins the WishBone Medical Board of Advisors. Dr. Kunkel has been a Consulting Surgeon for WishBone Medical helping to develop several new products and will continue in this role.  As a member of the Board of Advisors, he will be a part of an elite group of business people from around the World to provide strategic expertise and guidance for WishBone Medical. He is considered an expert in his field and was a team physician for the Indiana Pacers, Indiana Fever, USA Basketball, Depauw University and Brebeuf Jesuit Preparatory school.

He has been a practicing physician at OrthoIndy for over 30 years. OrthoIndy is one of the largest orthopedic practices in the world.  Dr. Kunkel consults for several healthcare companies and has developed several successful products.

Dr. Kunkel earned his Bachelor’s Degree from Indiana University and his Medical Degree from the Indiana University School of Medicine. He did his Internship at St. Mary’s Hospital in Grand Rapids, MI. and his Residency at Grand Rapids Orthopedic Surgery and Blodgett Memorial Medical Center. His fellowship was in Sports Medicine at the University of Toronto and at the University of Western Ontario in London, Ontario. He is certified by the American Board of Orthopaedics.

Nick Deeter, Chairman of the Board and CEO at WishBone Medical, said, “Dr. Kunkel brings his surgeon skills and entrepreneurial background to the WishBone Medical Board of Advisors. We look forward to working with Dr. Kunkel to not only develop successful pediatric products but also to help strategically guide WishBone Medical. Mr. Deeter added, “With his extensive background and experience, he will contribute to our mission of helping children globally with orthopedic issues.”

About WishBone Medical, Inc.

WishBone Medical is a Global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits to prevent infection, reduce overall costs for our customers and achieve the best outcomes for children around the world who are still growing.

For further information, visit or call Andrew Miclot, Vice-Chairman and President at 574-306-4006.


July 9, 2018 OrthoSpineNews

NEW YORKJuly 9, 2018 /PRNewswire-USNewswire/ — Researchers at Hospital for Special Surgery in New York City are launching a new study to identify inflammatory molecules that might help improve treatment of people with certain knee injuries.

The goals of the study, which is now enrolling patients, is to find biomarkers correlated with the development of osteoarthritis of the joint after surgery to fix traumatic tears of the meniscus. This horseshoe-shaped layer of cartilage cushions the bones of the knee during weight-bearing activities like running and jumping.

More than one million Americans annually undergo meniscal surgery, making it among the most common orthopedic procedures performed in the United States. The injuries generally occur in young athletes who experience violent trauma to the knee, although older people can suffer them without such trauma, as well. However, patients who undergo the procedure often develop osteoarthritis of the joint—a painful, degenerative condition that to date has no cure or particularly effective treatment.

“The bottom line is, this is a very common orthopedic surgery and the results are not very good,” said David W. Altchek, MD, sports medicine surgeon and co-chief emeritus of HSS Sports Medicine, and medical director for the New York Mets. “It seems like the surgery makes a small number of people better, some have an indifferent response and, unfortunately, a significant number of people get worse.”

“We don’t really know much about the biology of how the meniscus heals. We kind of let pain be the guide,” added Christopher Mendias, PhD, ATC, associate scientist at HSS, who is helping conduct the study. “We want to be able to say, ‘Is it healing well, and is there a correlation between doing poorly clinically and elevated levels of pro-inflammatory biomarkers or that we can detect with advanced imaging?'”

The HSS study will have several components. Drs. Altchek, Mendias and their colleagues will take samples of synovial fluid–a viscous substance that lubricates joints–from 28 patients (14 men and 14 women) aged 18 to 45 undergoing a procedure called partial meniscectomy in which surgeons shave away frayed pieces of the cartilage. Those samples will be screened for the presence of proteins associated with inflammation, molecules such as interleukin 1 beta, which is known to play a role in osteoarthritis, as well as other previously unidentified substances.

The researchers also will use an advanced form of magnetic resonance imaging to track meniscal healing over time, and will match that information with the biomarker activity to look for patterns of protein activity that predict either successful healing or poor outcomes.

“This whole idea of precision medicine is just kind of catching on in orthopedics now,” Dr. Mendias said. Ideally, a biomarker panel could help surgeons determine which patients will be most likely to benefit from particular meniscal procedures, and what kind of rehabilitation–and even prehabilitation–routine they should undergo. “It could also help us identify therapies to block those inflammatory molecules and reduce the risks of osteoarthritis later in life,” he said.

“The hypothesis is that there is a degenerative effect afterward, as a result of the injury or the surgery, or both—and that biologic therapy might slow that down,” Dr. Altchek said. He added that there is “a tremendous amount of excitement” in the field of orthopedics about new biologic therapies, including platelet rich plasma and stem cells, that are now being used to treat tendon injuries and certain other ailments. Whether they might work to treat or even prevent the development of osteoarthritis after knee surgery is unclear. “This project is an important step in the direction” of answering that question, he said.

Scott A. Rodeo, MD, sports medicine surgeon, co-chief emeritus of HSS Sports Medicine, and co-director of the Tissue Engineering, Regeneration, and Repair Program, will be contributing patients to the study.

“A common clinical observation is that there is tremendous variability in the rate and risk of progressive degenerative changes in patients undergoing surgery for meniscus injury,” said Dr. Rodeo, who also is head team physician for the New York Giants. “Some patients will do well for decades with no further problems, while there is a subset of patients who develop relatively rapid progression of degenerative changes. In addition to biomechanical factors, it is likely that the ‘biologic milieu’ in the joint is a major factor accounting for these discrepant outcomes. In this study we will characterize inflammatory mediators, matrix degrading enzymes, and a host of other cytokines that likely play an important role in joint homeostasis. Such information will not only help us gain a better understanding of the underlying mechanism of joint degeneration in patients with meniscus injury, but, importantly, may suggest therapeutic targets to allow development of innovative treatments.”

Other HSS physicians involved include HSS sports medicine surgeons Answorth A. Allen, MD, New York Knicks team physician; and Riley J. Williams III, MD, medical director of the Brooklyn Nets.

If you have a meniscus tear and are interested in the study, or would like to serve as a healthy control subject, please contact Daniel Edon (

About HSS | Hospital for Special Surgery

HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the eighth consecutive year) and No. 3 in rheumatology by U.S. News & World Report (2017-2018). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New JerseyConnecticut and in the Long Island and Westchester County regions of New York State. In 2017 HSS provided care to 135,000 patients from 80 countries and performed more than 32,000 surgical procedures. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Innovation Institute was formed in 2015 to realize the potential of new drugs, therapeutics and devices; the global standard total knee replacement was developed at HSS in 1969, and in 2017 HSS made 130 invention submissions (more than 2x the submissions in 2015). The HSS Education Institute provides continuing medical curriculum to more than 22.000 subscribing musculoskeletal healthcare professionals in 125 countries. Through HSS Global, the institution is collaborating with medical centers worldwide to advance the quality and value of care and to make world-class HSS care more accessible to more people.

SOURCE Hospital for Special Surgery

Related Links